Summary & Overview
HCPCS J2840: Injection, sebelipase alfa, 1 mg
HCPCS Level II code J2840 denotes injection of sebelipase alfa, 1 mg, an enzyme replacement therapy delivered via infusion. This code is used to bill for the drug product itself across outpatient infusion settings where biologic therapies are administered. Nationally, biologic infusions such as sebelipase alfa are high-cost, specialty-drug services with implications for coverage policies, prior authorization processes, and site-of-care determinations.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for sebelipase alfa, typical billing and service settings, common modifiers and claims considerations, and guidance on what information is available versus not provided in the input data. The publication outlines benchmarks and reimbursement context where available, highlights policy and coverage levers that commonly affect access to enzyme replacement therapies, and summarizes payer approaches to billing and authorization. Data not available in the input is identified explicitly so readers understand limitations of the presented information.
Billing Code Overview
HCPCS Level II code J2840 represents Injection, sebelipase alfa, 1 mg. This code denotes administration of sebelipase alfa, an enzyme replacement therapy used in clinical settings for infusion therapy.
-
Service type: Infusion/injectable biologic therapy
-
Typical site of service: Hospital outpatient infusion center, physician office infusion suite, or other outpatient infusion facility
Clinical & Coding Specifications
Clinical Context
A typical patient is an infant, child, or adult diagnosed with lysosomal acid lipase deficiency (LAL-D) requiring enzyme replacement therapy with sebelipase alfa. The patient presents to an outpatient infusion center or hospital outpatient infusion clinic for scheduled intravenous infusion. Prior to infusion, a certified infusion nurse performs medication verification, weight-based dose calculation, and pre-infusion assessment including vitals and review of prior infusion tolerance. Pre-medication (antipyretic, antihistamine, or corticosteroid) may be administered based on prior reactions. The infusion is delivered through a peripheral IV or central venous access device over a prescribed period per manufacturer and institutional protocol. Nursing documents start/stop times, lot number, and any adverse reactions. Post-infusion observation is completed per protocol and the patient is discharged with follow-up arranged with the metabolic/genetics or hepatology team. Billing is submitted using the HCPCS Level II code J2840 with appropriate modifiers to indicate special circumstances (for example, dose adjustments, discontinued therapy, or drug wastage) and linked to the patient’s primary diagnosis of LAL-D or related hepatic/lipid metabolic disorder in the claim.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug discarded/not administered to any patient | Use when any portion of the supplied drug vial is discarded and payer requires reporting of discarded drug. |